CN102596977B - 雷公藤内酯前药 - Google Patents

雷公藤内酯前药 Download PDF

Info

Publication number
CN102596977B
CN102596977B CN201080031839.1A CN201080031839A CN102596977B CN 102596977 B CN102596977 B CN 102596977B CN 201080031839 A CN201080031839 A CN 201080031839A CN 102596977 B CN102596977 B CN 102596977B
Authority
CN
China
Prior art keywords
cancer
compound
triptolide
formula
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080031839.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102596977A (zh
Inventor
I·G·乔格
S·P·帕蒂尔
A·K·萨卢加
R·楚
S·M·维克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of CN102596977A publication Critical patent/CN102596977A/zh
Application granted granted Critical
Publication of CN102596977B publication Critical patent/CN102596977B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201080031839.1A 2009-05-07 2010-05-07 雷公藤内酯前药 Active CN102596977B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17624909P 2009-05-07 2009-05-07
US61/176249 2009-05-07
PCT/US2010/034117 WO2010129918A1 (en) 2009-05-07 2010-05-07 Triptolide prodrugs

Publications (2)

Publication Number Publication Date
CN102596977A CN102596977A (zh) 2012-07-18
CN102596977B true CN102596977B (zh) 2016-06-29

Family

ID=42244313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080031839.1A Active CN102596977B (zh) 2009-05-07 2010-05-07 雷公藤内酯前药

Country Status (17)

Country Link
US (1) US8507552B2 (enExample)
EP (1) EP2427467B1 (enExample)
JP (3) JP6000122B2 (enExample)
KR (1) KR101821823B1 (enExample)
CN (1) CN102596977B (enExample)
AU (1) AU2010245669B2 (enExample)
BR (1) BRPI1014802B8 (enExample)
CA (2) CA2760953C (enExample)
DK (1) DK2427467T3 (enExample)
EA (1) EA021135B1 (enExample)
ES (1) ES2552163T3 (enExample)
MX (1) MX2011011776A (enExample)
MY (1) MY160392A (enExample)
PL (1) PL2427467T3 (enExample)
PT (1) PT2427467E (enExample)
SG (1) SG175885A1 (enExample)
WO (1) WO2010129918A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
DK3510860T3 (da) 2012-08-23 2021-10-18 Senestech Inc Nedsættelse af pattedyrs reproduktive kapacitet
WO2014047783A1 (zh) * 2012-09-25 2014-04-03 鼎泓国际投资（香港）有限公司 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
JP6931228B2 (ja) * 2015-09-11 2021-09-01 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と他の抗癌剤とを組み合わせた癌治療用組成物
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体（上海）有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN110551171B (zh) * 2018-05-31 2021-07-27 欣凯医药化工中间体（上海）有限公司 一种雷公藤内酯醇衍生物的制备方法
CN113056474A (zh) * 2018-09-13 2021-06-29 米尼阿姆里塔治疗学有限责任公司 用于治疗纤维化、nash和nafld的方法中的雷公藤内酯及其前药
WO2021221179A1 (ja) * 2020-04-28 2021-11-04 国立大学法人高知大学 ヒト膵癌オルガノイドを用いたマウスモデルの樹立
US20230303618A1 (en) 2020-08-21 2023-09-28 Reyoung Corporation Triptolide conjugates and uses thereof
CN115227829B (zh) * 2022-02-22 2023-10-13 成都中医药大学 酸敏感性适配体雷公藤甲素偶联物及应用
KR102821060B1 (ko) 2023-03-09 2025-06-16 미네암리타 테라퓨틱스, 엘엘씨 위암의 치료를 위한 약물 조합
KR20250154513A (ko) 2023-03-09 2025-10-28 미네암리타 테라퓨틱스, 엘엘씨 췌장암 치료용 약물 조합
WO2024187139A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1483731A (zh) * 2002-09-18 2004-03-24 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
WO2008108384A1 (ja) * 2007-03-06 2008-09-12 Eisai R & D Management Co., Ltd. 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物及びその製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
US5609991A (en) 1995-02-10 1997-03-11 Morton International, Inc. Photoimageable composition having improved alkaline process resistance and tack-free surface for contact imaging
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6548537B1 (en) 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
DE69909633T2 (de) * 1998-09-02 2004-05-13 Pharmagenesis, Inc., Palo Alto Gut wasserlösliche triptolid-prodrugs
AU3365800A (en) 1999-02-16 2000-09-04 Board Of Trustees Of The Leland Stanford Junior University Combined therapy of diterpenoid triepoxides and trail for synergistic killing oftumor cells
AU5368699A (en) 1999-04-16 2000-11-02 Chengdu Diao Pharmaceutical Group Company Limited Derivatives of triptolide, and preparation and uses thereof
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
UA77033C2 (uk) * 2001-12-21 2006-10-16 Mgi Gp Inc Спосіб отримання водорозчинних фосфонооксиметильних похідних спирту та фенолу
US7847109B2 (en) 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
AU2003297211A1 (en) 2002-12-17 2004-07-22 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
CN1223595C (zh) 2002-12-27 2005-10-19 中国科学院上海药物研究所 雷公藤内酯醇衍生物及其应用
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005020887A2 (en) 2003-06-27 2005-03-10 Pharmagenesis, Inc. Method for treatment of severe acute respiratory syndrome
US7820834B2 (en) 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
JP5252765B2 (ja) 2003-12-26 2013-07-31 学校法人東京薬科大学 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤
ATE554758T1 (de) 2004-03-02 2012-05-15 Pharmagenesis Inc Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs
US20070244080A1 (en) 2004-06-25 2007-10-18 Pharmagenesis, Inc. Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
WO2007025031A2 (en) * 2005-08-24 2007-03-01 Cephalon, Inc. Prodrugs of indanone and tetralone compounds
CN101049300A (zh) 2006-04-04 2007-10-10 中国科学院上海药物研究所 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用
FI20070574A0 (fi) * 2007-07-30 2007-07-30 Kuopion Yliopisto Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke
WO2009023201A1 (en) 2007-08-16 2009-02-19 Myelorx Llc Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1483731A (zh) * 2002-09-18 2004-03-24 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
WO2008108384A1 (ja) * 2007-03-06 2008-09-12 Eisai R & D Management Co., Ltd. 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物及びその製造方法

Also Published As

Publication number Publication date
CA2760953C (en) 2017-05-30
EP2427467A1 (en) 2012-03-14
EP2427467B1 (en) 2015-08-05
PL2427467T3 (pl) 2016-04-29
EA201190293A1 (ru) 2012-11-30
CA2760953A1 (en) 2010-11-11
MY160392A (en) 2017-03-15
WO2010129918A1 (en) 2010-11-11
ES2552163T3 (es) 2015-11-26
WO2010129918A8 (en) 2011-01-20
JP2014185181A (ja) 2014-10-02
JP6000122B2 (ja) 2016-09-28
AU2010245669A1 (en) 2011-12-01
KR20120015339A (ko) 2012-02-21
JP2016065099A (ja) 2016-04-28
US8507552B2 (en) 2013-08-13
MX2011011776A (es) 2012-08-03
BRPI1014802B1 (pt) 2020-09-24
AU2010245669B2 (en) 2015-11-26
KR101821823B1 (ko) 2018-01-24
CN102596977A (zh) 2012-07-18
HK1168107A1 (en) 2012-12-21
DK2427467T3 (en) 2015-11-09
CA2964631A1 (en) 2010-11-11
SG175885A1 (en) 2011-12-29
JP2012526148A (ja) 2012-10-25
BRPI1014802B8 (pt) 2021-05-25
PT2427467E (pt) 2015-11-19
BRPI1014802A2 (pt) 2016-04-05
US20120238529A1 (en) 2012-09-20
EA021135B1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
CN102596977B (zh) 雷公藤内酯前药
US10183033B2 (en) Triptolide prodrugs
JP7449913B2 (ja) オキサチアジン様化合物を作製する方法
CN106279321A (zh) 吉西他滨ProTide乏氧活化前药及其应用
CN101402667B (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
CN113230417B (zh) 葡萄糖和三苯基鏻修饰的脑肿瘤靶向脂质体的制备与应用
CN104910100A (zh) 化合物pac-1或其盐及包含它们的药物组合物
US20110251158A1 (en) Fullerene therapies for inflammation and inhibition of build-up of arterial plaque
JP7309608B2 (ja) 抗がん活性を有するステロイドサポニン
CN106854223A (zh) 氮芥槲皮素衍生物及其制备方法和用途
HK1168107B (en) Triptolide prodrugs
CN110960507B (zh) 低分子量肝素和天然药物前药构成的磷酸钙-脂质纳米药物共递送系统
JP2008540560A (ja) スチルベン誘導体並びにがん細胞増殖及び微生物増殖の阻害方法
CN104961794B (zh) 一种丹参酮iia衍生物及其制备和应用
WO2017012113A1 (zh) 化合物pac-1或其盐及包含它们的药物组合物
HK1147912B (en) Anti-inflammatory compounds and uses thereof
HK1147912A1 (en) Anti-inflammatory compounds and uses thereof
CN102649750A (zh) 姜黄素水杨酰单酯及其合成方法以及其在抗肿瘤、抗炎方面的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant